Thank you to everyone who participated in the 13th Annual Arnold and Madaleine Penner Musculoskeletal Research Symposium on November 6, 2024.

In a study published online on November 28, 2024, in The Lancet Oncology, Roberto Alejandro Sica, M.D., and colleagues report the results of the first clinical trial to evaluate this therapy. In the phase 1 trial, conducted at centers in the United States, Australia, and Canada, the CAR T-cell therapy, known as CTX130, was administered to 39 people previously treated for T-cell lymphomas. Forty six percent of patients responded to the therapy, with 6 achieving complete responses, and with higher doses yielding better response rates. A variety of serious but manageable side effects occurred. The results show that this type of CAR T-cell therapy is safe and effective for a subset of patients with T-cell lymphomas. A newer-generation CAR T-cell therapy, called CTX131, is now being studied at several medical centers including Montefiore Medical Center.

Dr. Sica is an assistant professor of oncology and of medicine at Einstein and a member of the National Cancer Institute–designated Montefiore Einstein Comprehensive Cancer Center.